What is Palmitoyl Tripeptide-1?
Palmitoyl Tripeptide-1 (Pal-GHK) is a synthetic lipopeptide consisting of a palmitoyl fatty acid chain attached to the tripeptide sequence Gly-His-Lys (GHK). This GHK sequence appears naturally in collagen I as a degradation fragment — when the extracellular matrix breaks down, GHK fragments act as damage signals that trigger repair processes in fibroblasts.
The palmitoyl group increases the molecule’s lipophilicity, aiding penetration through the stratum corneum into the dermis where fibroblasts reside.
Important: Palmitoyl Tripeptide-1 is a cosmetic ingredient, not a pharmaceutical. This page is for educational and formulation reference purposes. It is not medical advice.
Note on GHK-Cu vs. Pal-GHK
Palmitoyl Tripeptide-1 (Pal-GHK) is distinct from GHK-Cu (copper peptide):
- GHK-Cu includes a copper ion chelated to the GHK tripeptide and is studied for both injectable and topical applications with wound-healing and tissue-repair properties.
- Pal-GHK replaces the copper ion with a palmitoyl group, optimizing it for stratum-corneum penetration in cosmetic formulations. The copper-binding site is occupied and the molecule behaves differently from GHK-Cu.
Proposed mechanism of action
As a matrikine, Pal-GHK signals fibroblasts by interacting with receptors that respond to extracellular matrix fragments. Activation of these pathways has been associated in research models with:
- Increased synthesis of type I and III collagen (structural firmness)
- Upregulation of elastin production (skin elasticity)
- Stimulation of hyaluronic acid synthase (matrix hydration)
- Activation of matrix metalloproteinases (MMP-1, MMP-2) at low concentrations, which may support controlled matrix remodeling
This combination of synthesis stimulation and matrix remodeling makes it mechanistically complementary to Palmitoyl Tetrapeptide-7 (which suppresses excess inflammation and MMP activity), explaining the rationale for the Matrixyl 3000 pairing.
What the research says
Multiple in-vitro studies demonstrate fibroblast activation and collagen precursor upregulation. The Matrixyl 3000 complex (Pal-GHK + Pal-KTTKS) has been evaluated in at least two industry-sponsored clinical studies showing reductions in wrinkle volume and skin roughness over 2–3 months.
A 2017 review by Schagen categorized Palmitoyl Tripeptide-1 among better-evidenced topical peptides alongside Palmitoyl Pentapeptide-4. Independent peer-reviewed trials outside industry sponsorship remain limited.
Typical use in formulations
- Concentration range: 1–5 ppm in finished product (supplied pre-dissolved at higher percentages by ingredient houses like Sederma)
- Optimal pH: 5.0–7.0
- Solubility: Supplied as aqueous solution; the palmitoyl group is handled by the commercial pre-solubilization
- Target area: Full-face anti-aging, firmness loss, fine lines; particularly effective when collagen depletion (not just surface expression lines) is the primary concern
- Incompatibilities: Sensitive to aggressive oxidative conditions. Combine with antioxidants (tocopherol, ascorbyl glucoside) to preserve activity in formulation.
- Synergies: Designed to work as Matrixyl 3000 in combination with Palmitoyl Tetrapeptide-7. Can also be combined with Argireline for a dual approach covering both collagen synthesis and expression-line relaxation.
Cosmetic vs. pharmaceutical context
Pal-GHK is accepted as a cosmetic ingredient under FDA, EU Cosmetics Regulation, and comparable frameworks. It is the same GHK sequence as GHK-Cu but configured for cosmetic use, without the copper ion that gives GHK-Cu its additional wound-healing and ionic activity. Claims must remain cosmetic: “improves the appearance of firmness” rather than “stimulates collagen production.”
Reported protocol (research reference)
| Reported dose | Typically used at 1–5 ppm (0.0001–0.0005%) in finished formulations, often as part of the Matrixyl 3000 complex (combined with Palmitoyl Tetrapeptide-7). |
|---|---|
| FDA status | Not FDA approved |